AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31819405 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=128)
Number of subjects: 254
Study 28186618 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior fall
Number of subjects: 433
Study 28186618 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia
Number of subjects: 433
Study 28186618 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered nurses
Number of subjects: 433
Study 28186618 — intervention group
Group type: COMPARATOR
Intervention: Black resident photo
Number of subjects: 433
Study 25671655 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and PMR
Number of subjects: 64
Study 25671655 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus PMR
Number of subjects: 64
Study 25671655 — intervention group
Group type: COMPARATOR
Intervention: Education
Number of subjects: 64
Study 25671655 — intervention group
Group type: COMPARATOR
Intervention: PMR
Number of subjects: 64
Study 23897967 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured intervention (informational pamphlet and discussion)
Number of subjects: 120
Study 23897967 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 120
Study 22337213 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Number of subjects: 1684
Study 22337213 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 1684
Study 22337213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1684
Study 19406488 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary clinic intervention
Number of subjects: 45
Study 17374706 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ethinyl estradiol (15 microg/d)
Number of subjects: 14
Study 17374706 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ethinyl estradiol (15 microg/d)
Number of subjects: 14
Study 15798304 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive measurement of intrapulmonary shunt using oxygen uptake and pulmonary capillary blood flow measurement obtained by nitrous oxide rebreathing
Number of subjects: 9
Study 15798304 — intervention group
Group type: COMPARATOR
Intervention: Invasive standard measurement using mixed venous blood sampling
Number of subjects: 9
Study 12466695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (PSE) 120 mg
Number of subjects: 20
Study 12466695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9651906 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin alone (M group)
Number of subjects: 57
Study 9651906 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin and hormone replacement therapy (HRT) (MC group)
Number of subjects: 57
Study 8209274 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin/ifosfamide/cisplatin chemotherapy plus surgery
Number of subjects: 0
Study 8209274 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 3057850 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 50 or 100 mg
Number of subjects: 16
Study 3057850 — intervention group
Group type: EXPERIMENTAL
Intervention: nadolol 40 or 80 mg
Number of subjects: 16
Study 3057850 — intervention group
Group type: COMPARATOR
Intervention: nadolol
Number of subjects: 16
Study 3057850 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 16
Study 3057850 — intervention group
Group type: COMPARATOR
Intervention: both beta blockers
Number of subjects: 16
Study 29283099 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (G1) - Patients with unilateral SNHL and unilateral non-pulsatile tinnitus
Number of subjects: 3
Study 29283099 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (G2) - Patients with normal hearing and unilateral non-pulsatile tinnitus
Number of subjects: 3
Study 29283099 — intervention group
Group type: COMPARATOR
Intervention: Group 3 (G3) - Healthy volunteers with neither tinnitus nor hearing loss
Number of subjects: 3
Study 26849260 — intervention group
Group type: EXPERIMENTAL
Intervention: WM (education)
Number of subjects: 0
Study 26849260 — intervention group
Group type: EXPERIMENTAL
Intervention: WM+ (education plus counseling)
Number of subjects: 0
Study 26849260 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0
Study 26849260 — intervention group
Group type: COMPARATOR
Intervention: Observational control group
Number of subjects: 0
Study 25670206 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit with PN intervention
Number of subjects: 2390
Study 25670206 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitline referral
Number of subjects: 2390
Study 25670206 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 2390
Study 24119735 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir antiviral treatment (group A)
Number of subjects: 61
Study 24119735 — intervention group
Group type: COMPARATOR
Intervention: Natural resolution (group B)
Number of subjects: 61
Study 20395618 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil 5 mg/d
Number of subjects: 974
Study 20395618 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 974
Study 19288903 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (encircling acupuncture around affected focus, common acupuncture at Hegu (LI 4), Xuehai (SP 10), Fenglong (ST 40), Sanyinjiao (SP 6), venesection and cupping twice a week)
Number of subjects: 52
Study 19288903 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin Capsules (10 mg, t.i.d.)
Number of subjects: 52
Study 19288903 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (acupuncture and Western medicine)
Number of subjects: 52
Study 19288903 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 52
Study 17286116 — intervention group
Group type: EXPERIMENTAL
Intervention: Gollin test with incomplete figures and invisible masks
Number of subjects: 73
Study 17286116 — intervention group
Group type: EXPERIMENTAL
Intervention: Gollin test with increasing spectral similarity between figure and invisible mask
Number of subjects: 73
Study 17286116 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar figure or mask parameters
Number of subjects: 73
Study 12780424 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice plus iron supplement (60 mg Fe2+ or 3.6 mg heme iron plus 24 mg Fe2+)
Number of subjects: 326
Study 12780424 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice plus iron supplement (3.6 mg heme iron plus 24 mg Fe2+)
Number of subjects: 326
Study 12780424 — intervention group
Group type: COMPARATOR
Intervention: Advice only
Number of subjects: 326
Study 10798581 — intervention group
Group type: COMPARATOR
Intervention: B mixture (nutritionally balanced amino acid mixture)
Number of subjects: 39
Study 10798581 — intervention group
Group type: EXPERIMENTAL
Intervention: Phe/Tyr-free mixture (phenylalanine/tyrosine deficient mixture)
Number of subjects: 39
Study 10798581 — intervention group
Group type: EXPERIMENTAL
Intervention: Trp-free mixture (mixture deficient in tryptophan)
Number of subjects: 39
Study 1995766 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level IgG substitution (6 g l-1)
Number of subjects: 8
Study 1995766 — intervention group
Group type: COMPARATOR
Intervention: Low-level IgG substitution (3 g l-1)
Number of subjects: 8
Study 6830569 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradoxical Intention (PI)
Number of subjects: 26
Study 6830569 — intervention group
Group type: COMPARATOR
Intervention: Self-Statement Training (SST)
Number of subjects: 26
Study 30239822 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo-elicitation via a private Facebook group co-facilitated by a moderator and a patient-investigator who lives with chronic pain.
Number of subjects: 0
Study 29362212 — intervention group
Group type: EXPERIMENTAL
Intervention: Experts using high amounts of medical technical jargon (MTJ) in professional forums
Number of subjects: 98
Study 29362212 — intervention group
Group type: EXPERIMENTAL
Intervention: Experts using low amounts of medical technical jargon (MTJ) in advisory forums
Number of subjects: 98
Study 29362212 — intervention group
Group type: EXPERIMENTAL
Intervention: Experts using high amounts of medical technical jargon (MTJ) in advisory forums
Number of subjects: 98
Study 29362212 — intervention group
Group type: EXPERIMENTAL
Intervention: Experts in professional forums
Number of subjects: 98
Study 26519646 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable contraceptives
Number of subjects: 2830
Study 26519646 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 2830
Study 26519646 — intervention group
Group type: COMPARATOR
Intervention: Nonhormonal contraceptive method
Number of subjects: 2830
Study 24661167 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.80 g/kg ETOH)
Number of subjects: 0
Study 24661167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24661167 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic control beverage
Number of subjects: 0
Study 22159148 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute EPO administration (30,000 IU/d for 3 days)
Number of subjects: 16
Study 22159148 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic EPO administration (5000 IU/week for 13 weeks)
Number of subjects: 16
Study 20670234 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium 0.25 mg.kg(‐1) (Group Miva)
Number of subjects: 40
Study 20670234 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% 0.12 ml.kg(‐1) (Group Control)
Number of subjects: 40
Study 17515023 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture as an adjunct therapy for IVF
Number of subjects: 0
Study 17515023 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 0
Study 15468545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative monitoring with uncomplicated anesthetic management
Number of subjects: 375
Study 15468545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative monitoring with complicated adequate ventilation
Number of subjects: 375
Study 12124561 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMWHs)
Number of subjects: 0
Study 12124561 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study 12124561 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulants (OAs)
Number of subjects: 0
Study 9656866 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible hydrocolloid (alginate) impressions
Number of subjects: 0
Study 9656866 — intervention group
Group type: COMPARATOR
Intervention: Condensation silicone impressions
Number of subjects: 0
Study 7635996 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg intravenous bolus dose of triazolam
Number of subjects: 24
Study 7635996 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg oral doses of triazolam
Number of subjects: 24
Study 7635996 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20 mg oral dose of triazolam
Number of subjects: 24
Study 7635996 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg oral dose of triazolam
Number of subjects: 24
Study 7635996 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg oral doses of triazolam
Number of subjects: 24
Study 7635996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2677257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonidamine plus WBRT
Number of subjects: 58
Study 2677257 — intervention group
Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 58
Study 2677257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonidamine
Number of subjects: 58
Study 71604 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine during the first 6 postoperative days
Number of subjects: 42
Study 71604 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine (consecutively treated)
Number of subjects: 42
Study 71604 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 42
Study 71604 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-lignocaine cessation (7th to 14th postoperative days)
Number of subjects: 42
Study 29399993 — intervention group
Group type: EXPERIMENTAL
Intervention: in silico null mutations
Number of subjects: 231
Study 29399993 — intervention group
Group type: EXPERIMENTAL
Intervention: antigen-negative mutations
Number of subjects: 231
Study 28899522 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy with default settings
Number of subjects: 50
Study 28899522 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized actigraphy settings (10 consecutive immobile minutes for sleep onset or end and an activity threshold of 10)
Number of subjects: 50
Study 28899522 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 50
Study 25706652 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine viral load (VL) monitoring
Number of subjects: 820
Study 25706652 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (clinical and immunological monitoring)
Number of subjects: 820
Study 23803700 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 18
Study 23803700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21084254 — intervention group
Group type: COMPARATOR
Intervention: Bone turnover markers (OC, BALP, CTX) before treatment
Number of subjects: 55
Study 21084254 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone turnover markers during chemotherapy
Number of subjects: 55
Study 21084254 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone turnover markers after therapy
Number of subjects: 55
Study 19032727 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg kg(‐1) dexibuprofen
Number of subjects: 0
Study 19032727 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg kg(‐1) dexibuprofen
Number of subjects: 0
Study 19032727 — intervention group
Group type: COMPARATOR
Intervention: 10 mg kg(‐1) ibuprofen
Number of subjects: 0
Study 15736460 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious sedation without opiates
Number of subjects: 400
Study 15736460 — intervention group
Group type: COMPARATOR
Intervention: Conscious sedation with opiates
Number of subjects: 400
Study 12495164 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care provided by a pharmacist‐managed hypertension clinic
Number of subjects: 56
Study 12495164 — intervention group
Group type: COMPARATOR
Intervention: Standard care from their physicians
Number of subjects: 56
Study 9803103 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 G needle
Number of subjects: 125
Study 9803103 — intervention group
Group type: COMPARATOR
Intervention: 23 G needle
Number of subjects: 125
Study 9803103 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of 21 G and 23 G needles
Number of subjects: 125
Study 9803103 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 G needle and 23 G needle
Number of subjects: 125
Study 8572624 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant perioperative portal liver infusion with fluorouracil, mitomycin and heparin
Number of subjects: 0
Study 8572624 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant subclavian intravenous infusion with fluorouracil, mitomycin and heparin
Number of subjects: 0
Study 8572624 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (Control group)
Number of subjects: 0
Study 2510054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazedone (single-dose prophylactic administration)
Number of subjects: 50
Study 2510054 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 50
Study 794717 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 883
Study 794717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 883
Study 31554943 — intervention group
Group type: EXPERIMENTAL
Intervention: Conbercept (0.2 ml)
Number of subjects: 96
Study 31554943 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil (0.2 ml)
Number of subjects: 96
Study 30760161 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 12
Study 30760161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28566087 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency access button
Number of subjects: 0
Study 28566087 — intervention group
Group type: COMPARATOR
Intervention: Normal telephone waiting line
Number of subjects: 0
Study 24916013 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C plus B vitamins (400 µg folic acid, 2 mg B6, and 10 µg B12)
Number of subjects: 390
Study 24916013 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C (50 mg; control group)
Number of subjects: 390
Study 23643564 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional and cigarette-related pictures
Number of subjects: 180
Study 23643564 — intervention group
Group type: EXPERIMENTAL
Intervention: High-arousing erotic and mutilation pictures
Number of subjects: 180
Study 23643564 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-arousing pleasant and unpleasant objects
Number of subjects: 180
Study 23643564 — intervention group
Group type: COMPARATOR
Intervention: Cigarette stimuli containing people versus objects
Number of subjects: 180
Study 23643564 — intervention group
Group type: COMPARATOR
Intervention: Smokers versus never-smokers (N=40)
Number of subjects: 180
Study 21666543 — intervention group
Group type: EXPERIMENTAL
Intervention: Borg's Rating of Perceived Exertion (RPE) scale after managing a simulated critical incident
Number of subjects: 17
Study 21666543 — intervention group
Group type: COMPARATOR
Intervention: Borg's Rating of Perceived Exertion (RPE) scale during normal anaesthesia induction
Number of subjects: 17
Study 21666543 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability of the RPE scale for uneventful sessions
Number of subjects: 17
Study 19635338 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 34
Study 19635338 — intervention group
Group type: EXPERIMENTAL
Intervention: TSE
Number of subjects: 34
Study 19635338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 19635338 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 17109336 — intervention group
Group type: EXPERIMENTAL
Intervention: Study vaccine at 2 mg (n=5)
Number of subjects: 50
Study 17109336 — intervention group
Group type: EXPERIMENTAL
Intervention: Study vaccine at 4 mg (n=20)
Number of subjects: 50
Study 17109336 — intervention group
Group type: EXPERIMENTAL
Intervention: Study vaccine at 8 mg (n=15)
Number of subjects: 50
Study 17109336 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 50
Study 15236274 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercaptopurine 75 mg/m2 daily
Number of subjects: 226
Study 15236274 — intervention group
Group type: COMPARATOR
Intervention: Mercaptopurine 37.5 mg/m2 twice daily
Number of subjects: 226
Study 15236274 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of daily vs twice daily dosing
Number of subjects: 226
Study 12174398 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based health promotion interventions; specific details on dosage and duration not available.
Number of subjects: 0
Study 9401427 — intervention group
Group type: COMPARATOR
Intervention: 200 mg caffeine
Number of subjects: 12
Study 9401427 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 200 mg caffeine and a short nap
Number of subjects: 12
Study 9401427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8185426 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine hydrochloride‐isosorbide dinitrate combination therapy
Number of subjects: 0
Study 8185426 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril therapy
Number of subjects: 0
Study 8185426 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (digoxin and diuretic therapy)
Number of subjects: 0
Study 3583499 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine infusion with Method A
Number of subjects: 6
Study 3583499 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine infusion with Method B
Number of subjects: 6
Study 3583499 — intervention group
Group type: COMPARATOR
Intervention: Control experiments
Number of subjects: 6
Study 29770466 — intervention group
Group type: EXPERIMENTAL
Intervention: Withania somnifera
Number of subjects: 100
Study 29770466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 100
Study 29770466 — intervention group
Group type: COMPARATOR
Intervention: Intergroup comparison
Number of subjects: 100
Study 27524103 — intervention group
Group type: COMPARATOR
Intervention: Long schedule (3 months for hip or 6 months for knee prostheses)
Number of subjects: 63
Study 27524103 — intervention group
Group type: EXPERIMENTAL
Intervention: Short schedule (8 weeks)
Number of subjects: 63
Study 24709463 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (BLF) 100 mg/day
Number of subjects: 743
Study 24709463 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (BLF) 100 mg/day + Lactobacillus rhamnosus GG (LGG) 6×10(9) CFU/day
Number of subjects: 743
Study 24709463 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 743
Study 24173546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intercostal nerve block (ICNB) with 0.5% bupivacaine and 1/200,000 epinephrine
Number of subjects: 40
Study 24173546 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham block)
Number of subjects: 40
Study 24173546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intercostal nerve block (ICNB)
Number of subjects: 40
Study 20691707 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2, 10(‐6) to 10(‐9)M)
Number of subjects: 7
Study 20691707 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE, 10(‐5) to 10(‐7)M)
Number of subjects: 7
Study 20691707 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 7
Study 20691707 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVI vs LDF
Number of subjects: 7
Study 20691707 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between TIVI and LDF
Number of subjects: 7